Bristol-Myers Squibb Company

NYSE: BMY
$58.72
-$0.15 (-0.3%)
Real Time Data Delayed 15 Min.

BMY Articles

The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
The top analyst upgrades, downgrades and initiations seen on Thursday included Alphabet, American Water, Apple, Facebook, Macy's, Southern Copper, Twitter and YY.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Bristol-Myers Squibb shares dipped on Tuesday after the company reported results from its late-stage lung cancer study.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
Compugen shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb will make a $12 million equity investment as part of its collaboration on a cancer trial.
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.